Establishment Of A Biomarker To Test Molecular Risk Of Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$834,448.00
Summary
Less than 20% of patients live 5 years after a diagnosis of gastric cancer (GC). This is due to the advanced stage at the time of diagnosis. We have no markers to monitor therapy of cancer. This proposal aims to use next generation sequencing to find specific genetic changes in a persons tumour that can be used to monitor therapy. We aim to use the same technology to group patients into high-risk or low risk for development of GC. This will allow specific screening only for those at high-risk.
Structural Basis For Helicobacter Pylori Adhesion To Host Epithelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$665,328.00
Summary
The aim of this grant is to understand how the bacteria that cause gastric cancer and ulcers interact with the cells that line the stomach. This information will be used to develop new treatments to combat disease.
The intestinal lining is continuously renewed by specialised cells called intestinal stem cells. Stem cells throughout the body are regulated by nearby connective tissues. But, the identity of these supportive cells in the gut are unknown. We test whether a discrete population of connective tissue cells in the gut support intestinal stem cells. This project will identify new cellular therapies and targets to promote intestinal repair and manage intestinal cancer.
Vaccinating Against Helicobacter Pylori-induced Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,088,714.00
Summary
Stomach cancer is the 3rd leading cause of cancer-related deaths. Most stomach cancers result from inflammation due to Helicobacter pylori infection. Most infections are treatable with antibiotics but this does not protect against cancers that develop before infection is diagnosed. Normal vaccine approaches aimed at this infection have been unsuccessful. We have identified a new approach for protecting against stomach cancer by preventing inflammation; this project aims to develop this vaccine.
Understanding The Role Of B Cells In Gastric Cancer For The Design Of New Therapeutic Strategies
Funder
National Health and Medical Research Council
Funding Amount
$696,383.00
Summary
Gastric cancer is the 2nd most common cause of cancer-related death worldwide. Our laboratory has previously established clinically relevant mouse model of gastric cancers, and our preliminary results indicate a strong link between B cell tumor infiltration and gastric cancer progression. In this project, we aim to elucidate the role of B cells in gastric cancer and determine whether B-cell targeted therapy alone or in combination with chemotherapy can be beneficial against this malignancy.
Bridging The GAPP Between The Laboratory And Clinic To Prevent Gastric Adenocarcinoma And Proximal Polyposis Of The Stomach (GAPPS).
Funder
National Health and Medical Research Council
Funding Amount
$724,877.00
Summary
Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) is an inherited form of gastric cancer. Affected patients develop a large number of gastric polyps and are at risk of gastric cancer in their 30s. The only effective treatment is to surgically remove the stomach. Gastrectomy is, however, associated with significant post-operative complications. We will use laboratory and mouse models of GAPPS to identify acceptable new approaches to prevent cancer in these patients.
Pathophysiology Of Functional Dyspepsia: Integration Of Upper Gut Function, Inflammation And A Systems Biology Approach.
Funder
National Health and Medical Research Council
Funding Amount
$748,593.00
Summary
Functional dyspepsia (FD) is an extremely common and costly problem with no cure. We and others have found that inflammation and immune activation play a role in FD but to date no studies have linked these findings with well known diseases markers including disordered sensory and motor function or psychiatric comorbidity. This study will explore the interrelationships between inflammatory and immune mechanisms, disease markers as well as the microbiome. This study could unravel the cause of FD.
The TOPGEAR Trial; Trial Of Preoperative Therapy For Gastric And Esophagogastric Junction Adenocarcinoma
Funder
National Health and Medical Research Council
Funding Amount
$1,974,558.00
Summary
While surgery to remove gastric (stomach) cancer has been traditionally accepted as the only way to potentially cure the disease, there have been several recent advances using chemotherapy and/or radiotherapy both before and after surgery. However doctors' opinions remain divided regarding the best treatments to give and in what order. This randomised clinical trial will address the important question of whether combined chemotherapy plus radiotherapy is more effective than chemotherapy alone in ....While surgery to remove gastric (stomach) cancer has been traditionally accepted as the only way to potentially cure the disease, there have been several recent advances using chemotherapy and/or radiotherapy both before and after surgery. However doctors' opinions remain divided regarding the best treatments to give and in what order. This randomised clinical trial will address the important question of whether combined chemotherapy plus radiotherapy is more effective than chemotherapy alone in improving cure rates for stomach cancer.Read moreRead less
The FGFR Family As Drivers And Biomarkers Of Regorafenib Response In Gastric Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$670,784.00
Summary
The drug regorafenib has recently emerged as a potential new treatment for patients with gastric (stomach) cancer. We have discovered that gastric cancer cell lines which express high levels of members of the FGFR family are highly sensitive to this drug. This project will define the potential of targeting the FGFR family in gastric cancer,the value of FGFR1-4 as markers of regorafenib response, and develop strategies for enhancing regorafenib activity in this difficult to treat disease.
Modulating Gastrointestinal Function For Control Of Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$883,469.00
Summary
It is now recognized that gastrointestinal function, particularly the rate that meals empty from the stomach, and the secretion of hormones from the small intestine in response to nutrients, is fundamental to blood glucose control in people with diabetes. This project seeks to understand how these processes can best be modified by dietary or pharmaceutical means to improve blood glucose control and thereby prevent complications in type 2 diabetes